NCT00540215

Brief Summary

It is the study aim to investigate the effect of glp-2 on blood flow in humans. we wish to study eventual changes in renal blood flow, carotic blood flow and cardiac out put. GLP-2 will be administered subcutaneously, and the effect monitored by doppler ultra sound scannings and cotinuesly measuring of cardiac out put and blood pressure. The study will include 15 healhty volunteers, 10 wil receive 450 nmol GLP-2 and 5 will receive 1 ml of isotonic saline (as baseline reference).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2007

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2007

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

October 4, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 5, 2007

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2008

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2008

Completed
Last Updated

February 11, 2011

Status Verified

October 1, 2007

Enrollment Period

3 months

First QC Date

October 4, 2007

Last Update Submit

February 10, 2011

Conditions

Regional Blood Flow

Outcome Measures

Primary Outcomes (1)

  • effect of glp-2

    during study

Secondary Outcomes (1)

  • potential new ideas for further studies

    months to years

Study Arms (2)

1

ACTIVE COMPARATOR

450 nmol GLP-2 SC

Other: Glucagonlike peptide

2

PLACEBO COMPARATOR

1 ml isotonic saline SC

Other: Glucagonlike peptide

Interventions

Glucagonlike peptideOTHER

450 nmol native form, synthetic

12

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 20-60
  • Healthy
  • No medication
  • Not pregnant

You may not qualify if:

  • All of the persons not meeting the abowe mentioned criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Glostrup University Hospital

Glostrup Municipality, Capital Region, 2600, Denmark

Location

Study Officials

  • lasse bremholm, MD

    Glostrup university hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 4, 2007

First Posted

October 5, 2007

Study Start

October 1, 2007

Primary Completion

January 1, 2008

Study Completion

February 1, 2008

Last Updated

February 11, 2011

Record last verified: 2007-10

Locations

DK(1)